LeBlanc AJ, Touroo JS, Hoying JB, Williams SK. Adipose stromal vascular fraction cell construct sustains coronary microvascular function after acute myocardial infarction. Am J Physiol Heart Circ Physiol 302: H973-H982, 2012. First published December 2, 2011; doi:10.1152/ajpheart.00735.2011.-A three-dimensional tissue construct was created using adipose-derived stromal vascular fraction (SVF) cells and evaluated as a microvascular protection treatment in a myocardial infarction (MI) model. This study evaluated coronary blood flow (BF) and global left ventricular function after MI with and without the SVF construct. Fischer-344 rats were separated into four groups: sham operation (sham), MI, MI Vicryl patch (no cells), and MI SVF construct (MI SVF). SVF cells were labeled with green fluorescent protein (GFP). Immediately postinfarct, constructs were implanted onto the epicardium at the site of ischemia. Four weeks postsurgery, the coronary BF reserve was significantly decreased by 67% in the MI group and 75% in the MI Vicryl group compared with the sham group. The coronary BF reserve of the sham and MI SVF groups in the area at risk was not significantly different (sham group: 83 Ϯ 22% and MI SVF group: 57 Ϯ 22%). Griffonia simplicifolia I and GFP-positive SVF immunostaining revealed engrafted SVF cells around microvessels in the infarct region 4 wk postimplant. Overall heart function, specifically ejection fraction, was significantly greater in MI SVF hearts compared with MI and MI Vicryl hearts (MI SVF: 66 Ϯ 4%, MI: 37 Ϯ 8%, and MI Vicryl: 29 Ϯ 6%). In conclusion, adipose-derived SVF cells can be used to construct a novel therapeutic modality for treating microvascular instability and ischemia through implantation on the epicardial surface of the heart. The SVF construct implanted immediately after MI not only maintains heart function but also sustains microvascular perfusion and function in the infarct area by sustaining the coronary BF reserve. coronary circulation; microcirculation; tissue engineering; adipose; contractile function AFTER A MYOCARDIAL INFARCTION (MI), impaired microvascular blood flow (BF) results in a loss of cardiomyocyte function and, if untreated, can lead to widespread left ventricular (LV) contractile failure. Protecting the integrity and function of the microcirculation after MI remains a major target of cardiac regenerative medicine to prevent the progressive dysfunctional pathological changes that eventually lead to myocardial necrosis. The extent of the unviable myocardium within an infarct region after coronary vessel occlusion depends on several factors, including time to reperfusion, collateral vessel development potential, and possible ischemic preconditioning (25). The most traditional clinical treatment for acute MI is coronary revascularization of the infarct-related artery, specifically percutaneous coronary intervention (PCI), thrombolysis, or bypass surgery. However, as many as 48% of PCI patients do not regain distal microvascular perfusion even though the suspect artery is angiographically open (9). As such, there is a clinical need for treatments that are developed specifically with regard to coronary microcirculatory development, maintenance, and repair.
Protecting the integrity and function of the microcirculation after MI remains a major target of cardiac regenerative medicine to prevent the progressive dysfunctional pathological changes that eventually lead to myocardial necrosis. The extent of the unviable myocardium within an infarct region after coronary vessel occlusion depends on several factors, including time to reperfusion, collateral vessel development potential, and possible ischemic preconditioning (25) . The most traditional clinical treatment for acute MI is coronary revascularization of the infarct-related artery, specifically percutaneous coronary intervention (PCI), thrombolysis, or bypass surgery. However, as many as 48% of PCI patients do not regain distal microvascular perfusion even though the suspect artery is angiographically open (9) . As such, there is a clinical need for treatments that are developed specifically with regard to coronary microcirculatory development, maintenance, and repair.
Recent approaches to treat ischemia have focused on injection of suspensions of regenerative therapies including the direct injection of growth factors, cytokines, and/or progenitor cells. Cellular therapy has been limited by a lack of retention of the injected cells, as only ϳ1.3-2.6% of the transplanted cells are retained in the infarcted myocardium after intracoronary injection (11) . Additionally, a recent study by Hamdi et al. (10) showed that an adipose cell sheet implant resulted in greater postinfarct survival and greater cell engraftment than intramyocardial injections of the same cells. Therefore, more approaches have begun to focus on a combination of cell therapy and scaffolds to address the inadequate retention, survival, and integration of injected cells into the host tissue. Cellular and acellular cardiac patches (3, 14, 15) as well as injectable in situ geling materials (19) have all been explored for use as cardiac repair therapies focused on rebuilding myocardial tissue and/or microcirculatory repair. For example, muscle patches paired with genetically engineered mesenchymal stem cells (12) , progenitor cells combined with mesenchymal stem cells (8) , and bone marrow cells in a collagen matrix (5) have all been somewhat effective at improving overall heart function after MI compared with untreated hearts. Although increasing viable myocardial tissue remains critical to post-MI hearts, another major component of treatment should focus on coronary microcirculatory repair to supply adequate BF to transplanted cardiomyocytes.
Our laboratory has demonstrated a significant angiogenic response associated with the implantation of tissue-engineered patches directly onto the epicardial surface (13) . Specifically, a marked angiogenic response and improved cardiac function can be evoked by placing a construct of viable Dermagraft (a tissue-engineered Vicryl patch containing human dermal fibroblasts) onto the epicardial surface of a mouse heart that has been subjected to regional ischemic damage (13, 14) . Dermagraft elicits angiogenesis at the site of ischemic injury by secreting a myriad of angiogenic growth factors, such as VEGF, hepatocyte growth factor (HGF), and transforming growth factor (TGF)-␤ 1 (20) . Implanting this three-dimensional fibroblast matrix onto the epicardial surface of the heart post-MI resulted in smaller LV infarct size and improved LV function after treatment (30) . In addition, our laboratory has previously designed peripheral constructs to promote vascularization using isolated adipose-derived microvessel fragments (29, 30) . Indeed, both of these tissue-engineered treatments deliver promising results in terms of expanding the coronary microvasculature and lessening cardiac malfunction after MI; however, we believe that the potential for an autograft cell construct application in the treatment of MI would be a superior therapy due to the limitation and/or elimination of tissue inflammation and rejection.
Contained within adipose tissue is a regenerative, heterogeneous cell population defined as the stromal vascular fraction (SVF), consisting of endothelial cells, smooth muscle cells, blood cells, and mesenchymal cells (32) . SVF cells exhibits the potential to differentiate into various mesodermic lineages (17) and have demonstrated desirable characteristics as a cell population candidate for myocardial injury cell therapy. Therefore, our objective was to assess the coronary microcirculatory response of postinfarcted cardiac tissue to a degradable construct laden with adipose-derived SVF cells and to determine whether such a response is associated with a clinically significant improvement in cardiac performance. We hypothesized that a SVF cell construct implanted immediately after MI would help increase coronary perfusion in the infarct region, thereby improving overall cardiac function compared with untreated MI hearts.
METHODS

SVF isolation.
Green fluorescent protein (GFP)-tagged adult male Sprague-Dawley rats (Rat Research and Resource Center, University of Missouri, Columbia, MO) were put under anesthesia [ketamine (40 -80 mg/kg) and xylazine (5-10 mg/kg)]. GFP-positive SVF cells were isolated from epididymal fat pads. Harvested fat pads were washed in 0.1% BSA-PBS, finely minced, and digested in 2 mg/ml type I collagenase solution for 40 min at 37°C with vigorous shaking. Buoyant adipocytes were removed by centrifugation, and the entire cell pellet was suspended in 0.1% BSA-PBS. Cells were immediately plated (1 ϫ 10 6 cells/cm 2 ) onto a piece of Vicryl (1 ϫ 1.5 cm) and cultured for 14 days in DMEM with 10% FBS.
MI and construct implantation. All animal surgeries were performed in accordance with protocols approved by the Animal Review Committee of the University of Louisville and the National Institutes of Health. After anesthesia was introduced (1-3% isoflurane-balance O 2) and the lack of the toe pinch reflex was observed, the heart was exposed through a left lateral thoracotomy. Sham-operated (sham) animals were sutured close in three layers and allowed to recover. Infarcts were performed by left anterior descending coronary artery (LAD) ligation with 7-0 nylon suture (Ethicon) and confirmed via the visualization of blanched tissue distal to the ligation site. Infarcted animals were immediately randomized into one of the following three treatment groups: MI only, MI Vicryl, or MI SVF. A SVF construct was sewn directly onto the area of blanching for the MI SVF group (see below for details). MI Vicryl rats received a Vicryl-only implant (no cells). The chest was closed in three layers, and animals were allowed to recover and given buprinorphine (0.05 mg/kg) every 8 -12 h for the next 48 h. Endpoint parameters were assessed 4 wk after surgery after the injection of anesthesia [ketamine (40 -80 mg/kg) and xylazine (5-10 mg/kg)] and confirmation of the lack of a toe pinch reflex. Rats were euthanized by removal of the heart. Construct surgical implantation. After ligation of the LAD and the confirmation of distal blanching of the myocardial tissue, the SVF construct was removed from the incubator (37°C, 5% CO 2; Fig. 1B ) and placed directly on the epicardial surface. The SVF construct was malleable to the curvature of the heart and completely covered the area of infarct, overlapping slightly into the proximal noninfarcted region (Fig. 1C) . A single 7-0 silk suture was sewn immediately distal to the LAD occlusion site to minimize blood loss while the SVF construct was secured to the epicardial surface.
LV function assessment: pressure-volume loop analysis. Analysis of pressure-volume (PV) loop relationships of the LV used the Millar conductance system and was performed according to our previously published methods (30) . At the time of assessment, rats were anesthetized with an injection of ketamine (40 -80 mg/kg) and xylazine (5-10 mg/kg). A substernal transverse incision to expose the inferior vena cava was performed. An apical stab was used for catheter insertion and positioned along the cardiac longitudinal axis with the distal electrode in the aortic root and the proximal electrode in the LV apex. Placement of the catheter was monitored directly. Overall LV function was assessed by collecting heart rate, end-systolic pressure, end-diastolic pressure, ejection fraction (EF), stroke volume, endsystolic volume (ESV), end-diastolic volume (EDV), and cardiac output under baseline conditions, after transient inferior vena cava occlusion (to assess contractility and LV stiffness), and after the intravenous administration of 20 -40 l of 30% saline (for conductance volume calibration).
Myocardial BF assessment. For each measurement, 1.2 ϫ 10 6 nonradioactive elementally labeled 15-m microspheres (BioPal, Worcester, MA) were injected into the LV transapically while carotid blood was simultaneously sampled at a known withdrawal rate. This dose is well below the amount of spheres necessary to cause physiological effects in the heart; one estimate has suggested that several grams of microspheres are needed to induce physiological effects (4) . Two separate isotopes were injected transapically into the rat at the terminal point in the study (at 4 wk postsurgery): one at baseline and the other during a 5-min intravenous dobutamine injection (10 g·kg Ϫ1 ·min Ϫ1 ) (23) . Dobutamine is one of the most potent inotropes and is a cardioselective ␤-adrenoreceptor agonist and is often used in stress tests to detect the presence of hibernating myocardium in clinical chronic myocardial ischemia. The LV was harvested and sectioned into four radial slices from the apex to papillary muscle, and all but the apex was quartered. This sectioning allowed us to analyze BF in specific regions of the LV (i.e., the infarcted area, peri-infarcted region, and septal wall). Sections and blood samples were sent to BioPal for neutron activation, which is capable of simultaneously detecting a single microsphere in a variety of labeled isotopes in an intact myocardial sample (27) .
BF was calculated as follows: BF (in ml·min Ϫ1 ·g Ϫ1 ) ϭ {[withdrawal rate of the blood sample (in ml/min) ϫ dpm from tissue]/(dpm from blood sample)}/tissue weight (in g), where dpm represents disintegrations per minute. The withdrawal rate of the blood sample was set at 500 l/min for 2 min. The coronary BF reserve was calculated within each animal as a percentage of the baseline BF by the following equation: BF reserve (in %) ϭ (dobutamine BF Ϫ baseline BF)/(baseline BF) ϫ 100.
Histology and immunohistochemistry. Construct histology was accomplished by fixing constructs processing into paraffin. Cross sections (5-6 m thick) were stained with hematoxylin and eosin. The general histological structure of the heart was determined on deparaffinized 5-to 6-m-thick sections stained with Masson's trichrome. Infarct regions were manually traced and represented as percentage of the total LV area. Vascular endothelial cells were identified using a rodent-specific lectin [Griffonia simplicifolia I (GS-1)]. Vessel density was determined by counting discrete GS-1-positive structures from infarcted sections or the area at risk (ϳ1 mm proximal to the apex on the free wall of the LV). In each animal, five discrete random images (ϫ20 magnification) from the infarct region or area at risk were counted for GS-1-positive structures. For each image, the vessel count was divided by the area (in mm 2 ), resulting in counts/mm 2 . The total sum of counts/mm 2 was divided by 5 (images/animal) to get the average counts·mm Ϫ2 ·animal Ϫ1 . The counts·mm Ϫ2 ·animal Ϫ1 value was then averaged for each group.
To verify the presence of engrafted GFP-positive cells in MI SVF hearts, hearts were explanted 4 wk postsurgery, retroperfused with 4% paraformaldehyde and 30% sucrose solutions, fixed in Tissue-Tek (Sakura), and frozen in liquid nitrogen-cooled isopentane. Before being immunostained, hearts were sliced into 20-m-thick cross sections using an ultramicrotome (Leica) ϳ2 mm proximal to the apex. GFP-positive SVF cells were identified in the infarct area using an antibody directed against GFP (1:100, Invitrogen), whereas negative controls were incubated with a rabbit isotype control (1:100, Invitrogen). Primary antibody was detected by incubating the section with FITC-conjugated anti-rabbit IgG (1:100). Nonspecific binding fluorescence of negative control slides was subtracted from the remainder of GFP-positive immunostained slides. In addition, endothelial cell-comprised vessels were identified using rhodamine-labeled GS-1 (1:250, Vector Labs).
Quantitative real-time PCR. Cells from 14-day cultured SVF constructs were isolated from the Vicryl scaffold by a cell dissociation enzyme to determine what genes are upregulated in the SVF construct before implantation. Total RNA from SVF patches was isolated using the RNeasy minikit (Qiagen) after SVF cells were extracted from Vicryl using trypsin (1:10 dilution). To determine alterations in gene transcription after treatment with the SVF construct, LV RNA was isolated from the infarct region in both MI and MI SVF groups by homogenization followed by alcohol precipitation. Genes were chosen based on five categories deemed important in the potential mechanism of SVF construct action, such as promatrix formation [fibronectin-1 (Fn1) and laminin 5 (Ln5)], proangionenic factors [HGF (Hgf) and VEGF-A (Vegfa)], stem cell recruitment [stromal cell-derived factor (SDF)-1 (Sdf1) and c-Kit (Ckit)], proinflammatory factors [chemokine (C-X-C motif) receptor 4 (Cxcr4) and TNF-␣ (Tnfa)], and vasoactivity [endothelial nitric oxide synthase (Nos3) and thromboxane A 2 receptor (Tbxa2r)]. Gene primer sets are shown in Table 1 . RNA analysis was performed using the ⌬⌬C t method (where Ct is threshold cycle). The expression of each target mRNA relative to dynactin was calculated based on Ct as follows: ϭ 2 Ϫ⌬(⌬Ct ), where ⌬Ct ϭ Ct,target c-Kit 5=-GGCTAGCCAGAGACATCAGG-3= 5=-GAGCTCCCAGAGGAAAATCC-3= Chemokine (C-X-C motif) receptor 4 5=-CAAGCAAGGATGTGAGTTCG-3= 5=-ATGGAATTGAGTGCATGCTG-3= Endothelial nitric oxide synthase 5=-CTGCGGTGATGTCACTATGG-3= 5=-AGTCCGAAAATGTCCTCGTG-3= Fibronectin-1 5=-GGAGAGAAGTGGGATCGTCA-3= 5=-TGCCACTGTTCTCCTACGTG-3= Hepatocyte growth factor 5=-TGGCTGTACAATCCCTGAAA-3= 5=-AAGTCACCTTGCCTTGATGG-3= Laminin-5 5=-GCACCACTTTCCTTCTCACC-3= 5=-GGACAGGGACATGGTTGACT-3= Stromal cell-derived factor-1 5=-AGCCAGTCAGCCTGAGCTAC-3= 5=-TAATTTCGGGTCAATGCACA-3= TNF-␣ 5=-CAGCAGATGGGCTGTACCTT-3= 5=-GCTCTTGATGGCAGAGAGGA-3= Thromboxane A2 receptor 5=-GGGACTGTGAGGTGGAGATG-3= 5=-GAGGGGCTCATGACAGGTAG-3= VEGF 5=-CGGATCAAACCTCACCAAAG-3= 5=-TTTCTTGCGCTTTCGTTTTT-3=
Primers were designed with the Primer 3 web program (http://fokker.wi.mit.edu/cgi-bin/primer3/primer3_www_slow.cgi).
Ϫ Ct,dynactin. RNA expression for the MI SVF infarct area was made relative to the MI-only infarct area using the following equation:
Flow cytometric analysis. The phenotype of the cells isolated from SVF constructs was determined by assessing their surface markers using flow cytometric analysis. Cells were enzymatically released from 14-day cultured SVF constructs using trypsin (GIBCO). Antibodies included CXCR4 (a receptor for SDF-1), CD68 (a typical macrophage marker), CD45 (a leukocyte common antigen), the IL-4 receptor, major histocompatibility complex class II (a major histocompatibility complex typically found on macrophages), PDGF receptor-␤ (a growth factor that acts as a mitogen for cells of mesenchymal origin), vascular-endothelial cadherin (adhesion and angiogenesis), and VEGF receptor 2 (angiogenesis). The positive rate was calculated as the percentage of events above the isotype control for that particular antibody and were averaged with three measurements for each surface marker.
Statistical analysis. Mean differences between groups in all P-V loop parameters, infarct size, BF, coronary BF reserve, and vessel count were determined by ANOVA calculation. Post hoc analysis was determined by Tukey's test where appropriate.
RESULTS
Characterization of the SVF construct and LV infarct area after construct implantation. We wanted to further characterize the SVF construct to identify potential signaling mechanisms and compare gene expression with previous epicardial patches. Hematoxylin-eosin stain of a cross section of the SVF construct before implantation demonstrated cells throughout the depth of the construct, indicating that the 14-day culture time allows cells to disperse and not to be localized to one side (Fig.  1A) . Figure 1 , B and C, shows the construct before implantation and immediately after implantation on the epicardial surface, respectively. Figure 1D shows the explanted heart 30 days after MI ϩ SVF construct implantation. To better characterize gene expression of the SVF construct, we assessed both gene transcript and phenotypic surface markers of the 14- (Fig. 2A) . FACS analysis revealed that SVF construct cells (multiple constructs generated from the same initial adipose tissue isolation were used for 1 experiment, with 3 total isolations) exhibited a positive cell rate of 76.0 Ϯ 1.6% for CD68, a macrophage marker, and 31.3 Ϯ 2.3% for VEGF receptor 2, an angiogenic receptor marker (Fig. 2B) .
Heart remodeling and fibrosis after MI treatment. Histological evaluation of hearts that were implanted immediately with the SVF construct after ligation showed greater muscle fibers and less collagen and fibrosis than MI and MI Vicryl hearts (Fig. 3, A and B) . However, ANOVA comparisons between means did not reach the threshold for statistical significance (P ϭ 0.074 for MI vs. MI SVF and P ϭ 0.060 for MI vs. MI Vicryl; Fig. 3C ). This may be due to a decrease in LV free wall thickness in the area of infarct in both the MI and MI Vicryl groups, resulting in a lower infarct percentage of the total LV area than what Masson's trichrome-stained images exhibited (Fig. 3A) . To establish whether specific genes thought to be involved in improving heart function and angiogenesis were affected by SVF construct implantation, we measured gene expression (⌬⌬C t ) in the infarcted tissue from hearts after 4 wk without treatment (MI) and with the SVF construct (MI SVF). The MI ϩ SVF infarct area exhibited more than 1-fold increase in the expression of Fn1 and a 0.7-fold increase in Cxcr4 compared with MI only. Expression for Sdf1 (0.4-fold) as well as Nos3, Ln5, and Vegf (all 0.3-fold) were also increased in MI ϩ SVF tissue compared with untreated MI-only hearts. SVF construct placement at the time of ligation resulted in a significant negative fold change in the gene expression of Tnfa in LV infarct tissue after 4 wk, whereas Tbxa2r and Hgf were also decreased (Fig. 3D) .
Impact of construct implantation on overall heart function. Previous studies (14, 30) have determined that other cardiac patches implanted after MI attenuated the reduction in overall heart function compared with untreated hearts. Therefore, we wanted to determine if our SVF construct impacted overall LV function in a similar manner. P-V relationships were acquired after 4 wk of treatment and are shown in Fig. 4A . The P-V relationship was clearly shifted to the right in MI and MI Vicryl animals, due mainly to an increase in both ESV and EDV compared with sham and MI SVF groups. EF was significantly decreased in the MI and MI Vicryl groups by ϳ50% compared with the sham and MI SVF groups. Similar values were found between all groups in parameters such as heart rate, end-systolic pressure, end-diastolic pressure, and stroke volume (Fig. 4B) .
Regional microvascular perfusion and function after construct implantation. Further evaluation was conducted to determine if BF perfusion to the microcirculation, and specifically in the area of infarct, was associated with the assessment of overall heart function in all groups. After the infusion of microspheres, BF was determined in four radial slices from the apex to papillary muscle, and all but the apex was quartered. Quartering the radial slices allowed us to analyze BF in the area at risk, peri-infarct, septal wall, and noninfarcted LV wall. Implantation of an SVF-laden construct after MI sustained overall microcirculatory perfusion in the area of infarct during both baseline and dobutamine infusion to levels exhibited by sham control rats 4 wk postsurgery (Figs. 5 and 6A ). Figure 5 shows the overall BF changes in and around the area at risk for all groups during both baseline and dobutamine conditions. MI-only and MI Vicryl groups were associated with a 46% and 31% decline, respectively, in baseline BF to the area of infarct compared with the sham group, and this was significant in the MI-only group. Compared with the sham group, this deficiency persisted in the MI and MI Vicryl groups when challenged with dobutamine, resulting in ϳ55% less perfusion in the infarct region in both groups. There were no statistical differences in dobutamine-induced absolute BF between sham and MI SVF groups (Fig. 6A) . Additionally, the coronary BF reserve was sustained in MI SVF hearts (Fig. 6, C and D) . MI and MI Vicryl rats exhibited a significantly decreased coronary BF reserve compared with sham rats (61% and 75% decline, respectively; Fig. 6D ). To determine if the increase in blood perfusion was associated with an increase in the amount of Fig. 4 . Heart function as determined by pressure-volume (P-V) relationships. A: representative single P-V loop recording during baseline. B: summary of cardiac functional parameters. Sham (black) and MI SVF (red) hearts displayed similar heart function and P-V relationships. MI (green) and MI Vicryl (blue) hearts exhibited a rightward shift in the P-V relationship and decreased ejection fraction (EF) due to altered end-systolic volume (ESV) and enddiastolic volume (EDV) compared with sham and MI SVF hearts. HR, heart rate; CO, cardiac output; ESP, end-systolic pressure; EDP, end-diastolic pressure; SV, stroke volume. n Ն 4 rats/group. *Significantly different than the sham group (P Յ 0.05); †significantly different than the MI SVF group (P Յ 0.05). vessels in the infarct area, we counted GS-1-positive vascular elements from all groups (average of 5 fields/heart). Figure 6B shows the higher GS-1-positive count in the infarcted region of all MI groups compared with the sham group.
Cell engraftment. Four weeks after MI and SVF construct implantation, immunohistochemistry staining revealed the presence of engrafted GFP-positive SVF elements in the area of infarct (Fig. 7, middle) . Grafted cells were detected by anti-GFP immunostaining. In addition, endothelial cell-comprised vessels were identified through GS-1 staining (Fig. 7,  left) . The merged GFP and GS-1 images suggested that implanted GFP-positive SVF cells had migrated into the infarct area and specifically formed de novo vessels or were located around existing vascular elements within the myocardium (Fig.  7, right) .
DISCUSSION
Our goal was to develop a cardiac construct that can be used for the treatment of myocardial ischemia by targeting the coronary microcirculation. The principle findings from this study were fourfold. First, we created a three-dimensional adipose SVF cell construct that can be implanted on the epicardium after MI. Second, while all MI groups exhibited an increase in microvessel density in the area of infarct compared with the sham group, only MI hearts treated with the SVF construct exhibited a sustained coronary BF reserve 4 wk after the infarct. Third, clinical indexes of overall heart function, such as EF, ESV, and EDV, were significantly improved in the MI SVF group compared with the MI and MI Vicryl group.
Finally, engraftment of GFP-positive SVF cells was detected around vessels in the myocardium 4 wk after MI and SVF construct implantation. These data indicate that the SVF construct implanted immediately after MI not only maintained favorable cardiac function after MI but also protected the coronary microcirculation in the area of infarct to allow sustained coronary BF. The SVF construct is one of the first successful potentially autologous therapies shown to promote the development and/or maintenance of an ischemic and injured coronary microvasculature. The clinical potential of an autologous construct made from adipose-derived SVF is high, as the SVF construct may serve not only as a superior therapy in promoting microvessel survival and/or growth of new vessels after coronary infarct but also could be used in restoring the microcirculation to ischemic tissue in a variety of cardiomyopathies.
All MI groups demonstrated an increased number of GS-1-positive vessels in the area at risk (Fig. 6B) , but only the MI SVF group realized improved coronary BF (Fig. 6A) . Preliminary data from our laboratory has shown that adipose-derived SVF cells are capable of forming a de novo microvasculature and migrating into the vessel wall of existing neovessel segments to assemble parts of the vasculature (data not shown). It is likely that implantation of the SVF construct after MI promotes a positive angiogenic environment and helps accomplish functional neovascularization in the infarct region. In fact, this may be one means by which the SVF construct elicits improvements in vascular perfusion, as an immediate paracrine effect of the cells may help to initially stabilize the infarcted ) was evaluated by the injection of two different stable isotope-labeled microspheres during baseline and dobutamine infusion. After explant, LV rings above the apex were quartered, and the area at risk is indicated by the bracketed solid black lines in each of the MI groups. Blood perfusion in the area at risk was similar between the sham and MI SVF groups during both baseline and dobutamine conditions (n Ն 7 rats/group).
area, allowing for the eventual translocation of SVF cells from the construct. Alternately or in addition, once SVF construct cells have migrated into the vascular network of infarcted tissue (Fig. 7) , existing vessels in MI SVF hearts may thrive due to these secreted paracrines from the implanted SVF cells, as cells on the SVF construct exhibited an increase in relative gene expression associated with angiogenesis ( Fig. 2A) . Others have also pointed to this potential paracrine mechanism as a means to salvage cardiac function after MI. A dermal fibroblast construct (3DFC), similar to the SVF construct used in the present study, has also exhibited increased gene expression of angiogenesis-related growth factors, such as HGF and VEGF (2, 20) . Additionally, intracardiac injection of fat-derived stromal cells (lacking the vascular elements included in the present study) mediated improvement of myocardial regeneration through the secretion of a wide spectrum of angiogenic factors, such as VEGF, HGF, and angiopoietin-1 (7). Therefore, it is likely that the cells on the SVF construct immediately secrete angiogenic factors after implantation and/or migrate and stabilize the repairing vessels in the infarct region by the secretion of angiogenic factors after a MI. To determine this timedependent mechanistic action of the SVF construct, future studies should evaluate myocardial BF in the area of infarct at earlier time points. This would allow us to evaluate whether the SVF construct is able to improve regional BF at a time point more likely to promote myocardial salvage, in addition to the potential therapeutic mechanism through incorporation into the microvasculature shown in the present study.
Traditional therapies to address cardiac ischemia have focused primarily on restoring patency to occluded, upstream coronary arteries. However, reopening the occluded or stenotic coronary artery does not necessarily translate into improved cardiac perfusion in all clinical cases, despite angiographic evidence that the blockage was removed or bypassed (26) . This phenomenon is known as no reflow, and between 3.2% and 48% of patients with PCI-treated acute MI have shown this impairment of distal microcirculatory function without obstruction to BF (9, 28) . Resnic et al. (28) recently demonstrated that in patients undergoing PCI that those that developed this microcirculatory dysfunction after the procedure had a fivefold increased risk of MI and fourfold increased risk of death. Other studies (1, 24) have shown a similar increased risk for adverse events, and no reflow is now a powerful predictor of death or MI even after multivariable analysis. Therefore, treatment with a SVF construct in addition to traditional therapies may arrest the dysfunctional microcirculation and redirect beneficial coronary microvascular repair in a broad spectrum of cardiac conditions.
To completely assess the microvasculature, one needs to examine both structure and function. Measuring the coronary flow reserve (CFR) can assess both the structural and functional integrity of the microvasculature, and CFR is measured clinically through the use of a Doppler-tipped guidewire during both baseline and during hyperemic flow through a bolus injection of adenosine. A diminished CFR provides information about the ability of compensatory mechanisms for vaso- dilatory function of the myocardium. CFR has been correlated with the amount of viable myocardium after acute MI (21, 25) , LV systolic function (18) , and EF and in-hospital adverse cardiac events (22) . Shimada et al. (31) has shown that auspicious microvascular function during the convalescent stage after MI may positively affect remote stage functional and morphological outcomes of the LV. Other studies (9, 16) have demonstrated that the degree of microvascular damage after acute MI correlates with infarct size and subsequent functional recovery. Therefore, the most clinically significant finding in the present study is that post-MI treatment with the SVF construct sustained the coronary BF reserve (measured by dobutamine infusion) to sham levels, indicating that the microvasculature present in the infarct region of the myocardium can remain functional after MI and adequately provide tissue perfusion during the increased myocardial demand.
Simply demonstrating intact microvessels does not imply the functional integrity of these vessels, particularly after MI (25) . Surprisingly, we found an increased number of vessels in the infarct area in all MI groups compared with the sham group (Fig. 6B) . However, when these data are compared against microvascular BF, it becomes apparent that simply demonstrating increased vessel counts does not necessarily translate into microvascular function, as the MI and MI Vicryl groups were deficient in the coronary BF reserve (Fig. 6C) . Future studies evaluating post-MI proangiogenic therapies should be prepared to not only assess sum vessel counts but also to measure vascular function. Based on our present results, the SVF construct is ideal for proangiogenic therapy that results in not only an increased number of microvessels but functional microvascular perfusion to the area of infarct.
Although the present study demonstrates that implantation of a SVF construct immediately after coronary occlusion leads to favorable structural and functional outcomes, we realize that more clinically relevant time point studies should be performed regarding therapeutic timing post-MI. We chose to implant the SVF construct immediately after the MI to focus directly on the microvascular effects of the SVF construct in an area of acute ischemia. Our approach allowed us to avoid the complications of progressive, and sometimes irreversible, pathological changes that occur weeks or even months after a MI, such as cellular necrosis, scar tissue formation, and thinning of the outer LV wall (6) . In fact, gene expression analysis showed significant negative fold changes in Tnfa in the MI SVF infarct region compared with untreated MI hearts (Fig. 3E) . This suggests that immediate implant of the SVF construct can mitigate proinflammatory mechanisms in the infarct area after MI, but delaying the implant of a therapeutic device after MI may lead to different results. Interestingly, others (8) have previously shown that an epicardial construct consisting of progenitor and muscle cells implanted 30 days post-MI can still lead to improved angiogenesis and cell survival. Therefore, if we expand the tissue-engineered focus to incorporate muscle cells into the SVF construct, we could potentially strengthen the integrity of the construct and assist with the global LV contractile changes that occur after chronic MI. Additionally, a catheter-based delivery of our SVF construct would certainly maximize its therapeutic and clinical potential.
Direct delivery of regenerative cells, as well as direct injection of growth factors, cytokines, and/or other progenitor cells, has been limited by the early death of injected cells, as only ϳ1.3-2.6% of the transplanted cells are retained in the infarcted myocardium after intracoronary injection (3). However, catheter-based injectable materials offer a unique solution to delivering cells directly to the infarcted area while simultaneously addressing the necessity of lasting cell-matrix interactions within the myocardium. Additionally, another catheterbased method currently patent pending would allow for the implantation and deployment of segments of the Vicryl-based SVF construct endocardially. We foresee these types of catheter-based approaches as a means to deliver multiple segments of the SVF construct into the infarcted area endocardially. Since the SVF construct was associated with sustained microvascular perfusion after epicardial implantation in the area of infarct, we anticipate similar results if the SVF construct was used as a therapeutic cell delivery system to areas around the endocardial infarct region in a catheter-based approach. This approach would allow the utilization of the SVF construct during more frequently performed and preferred closed-chest procedures compared with open-chest surgeries.
In summary, we have shown that therapeutic treatment with the SVF construct after an acute MI results in greater microvascular perfusion to the area of infarct 4 wk after occlusion. Presumably, the improved microcirculatory function prevented the progression of the infarct, thereby preserving overall cardiac function. Numerous other studies have linked favorable microvascular status with increased viable myocardium after acute MI (21, 25) , LV systolic function (18) , and an improved EF and a decrease in in-hospital adverse cardiac events (22) . It is important to note that the SVF construct therapy is fully autologous, and adipose tissue serves as an abundant, surgically accessible, and regenerative cell-rich source. With some minor changes, the SVF construct is amenable to a number of delivery approaches, including multiple catheter-based procedures. The SVF construct can be a provascular therapy in many types of ischemic and infarcted conditions, including angina, no reflow, and coronary microvascular dysfunction in addition to other peripheral ischemic diseases.
